Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：24

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 50 条

[41] Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors
Perez-Santos, Martin
PHARMACEUTICAL PATENT ANALYST, 2020, 9 (05) : 149 - 154
[42] The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
Wang, Xuan
Ji, Qing
Yan, Xieqiao
Lian, Bin
Si, Lu
Chi, Zhihong
Sheng, Xinan
Kong, Yan
Mao, Lili
Bai, Xue
Tang, Bixia
Li, Siming
Zhou, Li
Cui, Chuanliang
Guo, Jun
FRONTIERS IN ONCOLOGY, 2020, 10
[43] Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Wei, Spencer C.
Anang, Nana-Ama A. S.
Sharma, Roshan
Andrews, Miles C.
Reuben, Alexandre
Levine, Jacob H.
Cogdill, Alexandria P.
Mancuso, James J.
Wargo, Jennifer A.
Pe'er, Dana
Allison, James P.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (45) : 22699 - 22709
[44] Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
Patrinely, James R., Jr.
Baker, Laura X.
Davis, Elizabeth J.
Song, Haocan
Ye, Fei
Johnson, Douglas B.
CANCER, 2020, 126 (15) : 3448 - 3455
[45] Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
Muto, Yusuke
Kambayashi, Yumi
Kato, Hiroshi
Fukushima, Satoshi
Ito, Takamichi
Maekawa, Takeo
Fujisawa, Yasuhiro
Yoshino, Koji
Uchi, Hiroshi
Matsushita, Shigeto
Yamamoto, Yuki
Amagai, Ryo
Ohuchi, Kentaro
Hashimoto, Akira
Fujimura, Taku
ACTA DERMATO-VENEREOLOGICA, 2022, 102
[46] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
Kaehler, Katharina C.
Hassel, Jessica C.
Heinzerling, Lucie
Loquai, Carmen
Moessner, Rotraut
Ugurel, Selma
Zimmer, Lisa
Gutzmer, Ralf
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
[47] Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
Azuma, Takeshi
Takeuchi, Takumi
Matayoshi, Yukihide
Namiki, Shin
Obara, Tetsuya
Imamura, Kazuhiro
Takamori, Mikio
SCIENTIFIC REPORTS, 2021, 11 (01)
[48] Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
Zhu, Meiyan
Jin, Meng
Zhao, Xiao
Shen, Shunli
Chen, Yihan
Xiao, Han
Wei, Guangyan
He, Qiang
Li, Bin
Peng, Zhenwei
BMC MEDICINE, 2024, 22 (01)
[49] Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
Zhao, Lingdi
Yang, Yonghao
Ma, Baozhen
Li, Wei
Li, Tiepeng
Han, Lu
Zhang, Yong
Shang, Yi-Man
Lin, Hongwei
Gao, Quanli
JOURNAL OF ONCOLOGY, 2019, 2019
[50] Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Sove, Richard J.
Verma, Babita K.
Wang, Hanwen
Ho, Won Jin
Yarchoan, Mark
Popel, Aleksander S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (11)

← 1 2 3 4 5 →